サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1159192

真性多血症後骨髄線維症（PPV-MF）の世界市場（2022年～2028年）

Post Polycythemia Vera Myelofibrosis (PPV-MF) Market 2022-2028
出版日: | 発行: Orion Market Research | ページ情報: 英文 120 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
真性多血症後骨髄線維症（PPV-MF）の世界市場（2022年～2028年）
出版日: 2022年09月21日
発行: Orion Market Research
ページ情報: 英文 120 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の真性多血症後骨髄線維症（PPV-MF）の市場規模は、予測期間中に9.1%のCAGRで成長すると予想されています。悪性細胞の増殖の制御をサポートし、この状態に苦しむ患者の回復プロセスを加速させる技術の開発とともに、人々の意識の高まりが市場の成長を促進しています。

当レポートでは、世界の真性多血症後骨髄線維症（PPV-MF）市場について調査分析し、市場概要、競合情勢、市場分析、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 レポートの概要

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向

第3章 競合情勢

  • Abbvie Inc.
  • Celgene Corp.
  • CTI BioPharma Corp.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • 主要戦略分析
  • COVID-19が主要企業に与える影響

第4章 市場セグメンテーション

  • 真性多血症後骨髄線維症（PPV-MF）市場：タイプ別
    • デュルバルマブ
    • ジビノスタット
    • グラスデギブ
    • イデラリシブ
    • IMG-7289
    • その他
  • 真性多血症後骨髄線維症（PPV-MF）市場：用途別
    • 病院
    • クリニック
    • その他

第5章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋
  • 世界のその他の地域

第6章 企業プロファイル

  • Incyte Corp.
  • Italfarmaco SpA
  • JW Pharmaceutical Corp.
  • Kartos Therapeutics Inc.
  • Karyopharm Therapeutics Inc.
  • Lynk Pharmaceutical Hangzhou Co. Ltd.
  • Medimmune LLC
  • MEI Pharma Inc.
  • Merck & Co Inc.
  • Novartis AG
  • NS Pharma Inc.
  • Promedior Inc.
  • Rhizen Pharmaceuticals AG
  • Samus Therapeutics Inc.
  • Sierra Oncology Inc.
  • Sino Biopharmaceutical Ltd.
  • Sun Pharma Advanced Research Co. Ltd.
  • Suzhou Zelgen Biopharmaceutical Co Ltd.
図表

LIST OF TABLES

  • 1. GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL DURVALUMAB POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL GIVINOSTAT POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL GLASDEGIB POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 5. GLOBAL IDELALISIB POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL IMG-7289 POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBAL OTHERS POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 9. GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET FOR HOSPITAL RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 10. GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET FOR CLINIC RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 11. GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET FOR OTHERS RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 12. GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
  • 13. NORTH AMERICAN POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 14. NORTH AMERICAN POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 15. NORTH AMERICAN POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 16. EUROPEAN POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 17. EUROPEAN POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 18. EUROPEAN POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 19. ASIA-PACIFIC POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 20. ASIA-PACIFIC POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 21. ASIA-PACIFIC POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 22. REST OF THE WORLD POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 23. REST OF THE WORLD POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 24. REST OF THE WORLD POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. IMPACT OF COVID-19 ON GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET, 2021-2028 ($ MILLION)
  • 2. IMPACT OF COVID-19 ON GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET BY SEGMENT, 2021-2028 ($ MILLION)
  • 3. RECOVERY OF GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET, 2022-2028 (%)
  • 4. GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SHARE BY TYPE, 2021 VS 2028 (%)
  • 5. GLOBAL DURVALUMAB POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 6. GLOBAL GIVINOSTAT POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 7. GLOBAL GLASDEGIB POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 8. GLOBAL IDELALISIB POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 9. GLOBAL IMG-7289 POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 10. GLOBAL OTHERS POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 11. GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
  • 12. GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET FOR HOSPITAL, SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 13. GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET FOR CLINIC, SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 14. GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET FOR OTHERS, SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 15. GLOBAL POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
  • 16. US POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
  • 17. CANADA POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
  • 18. UK POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. FRANCE POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. GERMANY POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. ITALY POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
  • 22. SPAIN POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
  • 23. REST OF EUROPE POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
  • 24. INDIA POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
  • 25. CHINA POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
  • 26. JAPAN POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
  • 27. SOUTH KOREA POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
  • 28. REST OF ASIA-PACIFIC POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
  • 29. REST OF THE WORLD POST POLYCYTHEMIA VERA MYELOFIBROSIS (PPV MF) MARKET SIZE, 2021-2028 ($ MILLION)
目次
Product Code: OMR2026092

Global Post Polycythemia Vera Myelofibrosis (PPV MF) Market Size, Share, and Trends Analysis Report By Type (Durvalumab, Givinostat, Glasdegib, Idelalisib, IMG-7289, and Others), By Application (Hospital, Clinic, and Others), Forecast 2022-2028

The global post polycythemia vera myelofibrosis (PPV MF) market is anticipated to grow at a substantial CAGR of 9.1% during the forecast period. Increased awareness among people along with technological developments such as gene editing which will support control of the proliferation of malignant cells and accelerate the recovery process for patients suffering from this condition will further boom the PPV MF market.

The global post polycythemia vera myelofibrosis (PPV MF) market is segmented based on Type and Application. By type, the market is segmented into durvalumab, givinostat, glasdegib, idelalisib, IMG-7289, and others. Based on the application, the market is sub-segmented into hospital, clinic, and others. Among the above segment, by application, the hospital segment is holding a significant market share during the forecast period owing to the increased incidence or prevalence of hematological malignancies and the requirement for stringent care protocols. Furthermore, hospital use ground zero for the treatment process where patients undergo chemotherapy with stem cell transplantation which requires high-level expertise and specialized equipment. Thus, these are the few reasons that drive the PPV MF market in this segment.

Geographically, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America has a prominent share in the market which is followed by Europe the in the market. The increasing healthcare developments and growing awareness among people is acting as important factors that are driving the growth of the European region in the market.

The major companies serving the global post polycythemia vera myelofibrosis (PPV MF) market include AbbVie Inc., Celgene Corp., CTI BioPharma Corp., F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., and Others. Players in the market are markedly contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in February 2022, CTI BioPharma Corp. announced that the U.S. Food and Drug Administration has approved VONJO (pacritinib) for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 * 10^9/L. VONJO is a novel oral kinase inhibitor with specificity for JAK2 and IRAK1, without inhibiting JAK1. The recommended dosage of VONJO is 200 mg orally twice daily. VONJO is the first approved therapy that specifically addresses the needs of patients with cytopenic myelofibrosis.

Research Methodology

The market study of the global post polycythemia vera myelofibrosis (PPV MF) market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives as possible, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Post Polycythemia Vera Myelofibrosis (PPV MF) Market Research and Analysis by Type

2. Global Post Polycythemia Vera Myelofibrosis (PPV MF) Market Research and Analysis by Application

The Report Covers:

  • Comprehensive Research Methodology of the global post polycythemia vera myelofibrosis (PPV MF) market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global post polycythemia vera myelofibrosis (PPV MF) market.
  • Insights about market determinants that are stimulating the global post polycythemia vera myelofibrosis (PPV MF) market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • Impact of COVID-19 on The Global Post Polycythemia Vera Myelofibrosis (PPV MF) Market
  • Recovery Scenario of Global Post Polycythemia Vera Myelofibrosis (PPV MF) Market
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. BY Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Abbvie Inc.
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Celgene Corp.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. CTI BioPharma Corp.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. F. Hoffmann-La Roche Ltd.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Gilead Sciences Inc.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Key Strategy Analysis
  • 3.7. Impact of Covid-19 on Key Players

4. Market Segmentation

  • 4.1. Global Post Polycythemia Vera Myelofibrosis (PPV MF) Market by Type
    • 4.1.1. Durvalumab
    • 4.1.2. Givinostat
    • 4.1.3. Glasdegib
    • 4.1.4. Idelalisib
    • 4.1.5. IMG-7289
    • 4.1.6. Others
  • 4.2. Global Post Polycythemia Vera Myelofibrosis (PPV MF) Market by Application
    • 4.2.1. Hospital
    • 4.2.2. Clinic
    • 4.2.3. Others

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Incyte Corp.
  • 6.2. Italfarmaco SpA
  • 6.3. JW Pharmaceutical Corp.
  • 6.4. Kartos Therapeutics Inc.
  • 6.5. Karyopharm Therapeutics Inc.
  • 6.6. Lynk Pharmaceutical Hangzhou Co. Ltd.
  • 6.7. Medimmune LLC
  • 6.8. MEI Pharma Inc.
  • 6.9. Merck & Co Inc.
  • 6.10. Novartis AG
  • 6.11. NS Pharma Inc.
  • 6.12. Promedior Inc.
  • 6.13. Rhizen Pharmaceuticals AG
  • 6.14. Samus Therapeutics Inc.
  • 6.15. Sierra Oncology Inc.
  • 6.16. Sino Biopharmaceutical Ltd.
  • 6.17. Sun Pharma Advanced Research Co. Ltd.
  • 6.18. Suzhou Zelgen Biopharmaceutical Co Ltd.